Baiocchi 2006.

Methods	Randomised clinical trial
Participants	Country: Italy Number randomised: 20 Postrandomisation dropouts: 0 (0%) Revised sample size: 20 Average age: 49 years Females: 5 (25%) Primary transplantation: 20 (100%) Retransplantation: 0 (0%) HCV: 8 (40%) HBV: 4 (20%) Alcoholic cirrhosis: 3 (15%) Other causes: 1 (5%) Average follow‐up period in months (for all groups): 3 Additional treatment such as antiviral drugs: lamivudine in HBV patients Important inclusion and exclusion criteria Primary transplantation only: yes Retransplantation only: no HCV only: no HBV only: no Alcoholic cirrhosis only: no Other causes: yes Other important inclusion criteria: Elective transplantation Important exclusion criteria: Multi‐organ transplantation
Interventions	Participants were randomly assigned to 2 groups. Group 1: cyclosporine A (n = 10). Further details: cyclosporine A: attain 250 ng/mL. Group 2: tacrolimus (n = 10). Further details: tacrolimus: attain 10 ng/mL.
Outcomes	None of the outcomes of interest were reported.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias)	High risk	Comment: no published protocol was available; either mortality/graft loss or adverse events, or both were not reported.
For‐profit bias	Unclear risk	Comment: this information was not available.
Other bias	Low risk	Comment: no other bias noted.